Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280999 | 0.89 | KCNH3 (1.00) | KCNH3 | |
| SCHEMBL535908 | 0.85 | KCNH3 (1.00) | KCNH3 | |
| SCHEMBL540957 | 0.83 | KCNH3 (0.86) | KCNH3ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1923730 | 0.81 | KCNH3 (0.98) | KCNH3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1923780 | 0.81 | KCNH3 (0.81) | KCNH3ALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL3411999 | 0.80 | KCNH3 (1.00) | KCNH3 | |
| SCHEMBL5017676 | 0.79 | KCNH3 (0.69) | KCNH3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1923771 | 0.76 | KCNH3 (0.82) | KCNH3MEN1KMT2AMAPTGAA | |
| SCHEMBL11812041 | 0.75 | MAPT (0.81) | KCNH3ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1924396 | 0.75 | KCNH3 (0.83) | KCNH3ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479397-B1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-06-08 | — | — | EP | claimed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | claimed |
| US-20120088772-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | ASTELLAS PHARMA INC. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20100256152-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256152-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA | KCNAB1, KCNN1, SCN1A | KCNH3 81/4885ALDH1A1 3513/4885MEN1 3776/4885 |
| US-20120088772-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | SLC6A3, ATP1A2, SLC6A1 | KCNH3 105/4885ALDH1A1 722/4885MEN1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.